Evaluation of current therapeutic strategies in Behçet's disease

Clinical Rheumatology

Volumn 30, Issue 2, 2011, Pages 157-163

  Alexoudi, Iliana ^a   Kapsimali, Violetta ^b   Vaiopoulos, Aristides ^a   Kanakis, Meletios ^a   Vaiopoulos, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Behcet's disease; Biologic agents; Management; Organs; Therapy; Treatm

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; AZATHIOPRINE; BENZATHINE PENICILLIN; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; DOXYCYCLINE; ETANERCEPT; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LOCAL ANESTHETIC AGENT; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PREDNISONE; SALAZOSULFAPYRIDINE; STEROID; SUCRALFATE; TACROLIMUS; TETRACYCLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

APHTHOUS STOMATITIS; ARTHRITIS; AUTOIMMUNE DISEASE; BEHCET DISEASE; CARDIOVASCULAR DISEASE; CEREBRAL SINUS THROMBOSIS; CLINICAL FEATURE; DRUG MEGADOSE; ENTERITIS; ERYTHEMA NODOSUM; EYE DISEASE; FLU LIKE SYNDROME; GENITAL ULCER; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTRACRANIAL HYPERTENSION; IRIDECTOMY; IRIDOCYCLITIS; LASER COAGULATION; LASER SURGERY; LOW DRUG DOSE; MOUTH ULCER; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETINA VASCULITIS; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SYSTEMIC THERAPY; TERATOGENESIS; TOPICAL TREATMENT; UVEITIS; VISUAL ACUITY; VITRECTOMY;

BEHCET SYNDROME; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS;

EID: 79954451021     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1566-4     Document Type: Review

References (49)

1. Alpsoy E, Akman A (2009) Behçet's disease: an algorithmic approach to its treatment. Arch Dermatol Res 301:693-702.
2. Ahmad T, Wallace GR, James T et al (2003) Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms? Arth Rheum 48:807-813. (Pubitemid 36302019)
3. Ceyran H, Akcali Y, Kahraman C (2003) Surgical treatment of vasculo-Behçet's disease. A review of patients with concomitant multiple aneurysms and venous lesions. Vasa 32:149-153. (Pubitemid 37127825)
4. Kapsimali V, Kanakis M, Vaiopoulos G, et al (2010) Etiopathogenesis of Behçet's disease with emphasis on the role of immunological aberrations. Clin Rheumatol (in press).
5. Calamia KT, Kaklamanis PG (2008) Behçet's disease: recent advances in early diagnosis and effective treatment. Curr Rheumatol Rep 10:349-355.
6. Gul A (2007) Standard and novel therapeutic approaches to Behçet's disease. Drugs 67:2013-2022. (Pubitemid 47524563)
7. Sfikakis PP, Theodossiadis PG, Katsiari CG et al (2001) Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 358:295-296. (Pubitemid 32738970)
8. Lynde CB, Bruce AS, Rogers RS 3rd (2009) Successful treatment of complex aphthosis with colchicine and dapsone. Arch Dermatol 145:273-276.
9. Debol SM, Herron MJ, Nelson RD (1997) Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol 62:827-836. (Pubitemid 28015631)
10. Kaklamanis P, Kaklamani V (2001) Treatment of Behçet's disease- an update. Semin Arth Rheum 30:299-312.
11. Hatemi G, Silman A, Bang D et al (2009) Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. Ann Rheum Dis 68:1528.
12. Seyahi E, Fresko I, Yazici H et al (2006) The management of Behcet syndrome. Acta Rheum Port 31:125-131.
13. Lin P, Liang G (2006) Behçet disease: recommendation for clinical management of mucocutaneous lesions. J Clin Rheumatol 12:282-286. (Pubitemid 44915326)
14. Duygulu F, Evereklioglu MM et al (2005) Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behçet's disease: a pilot study. Clin Rheumatol 24:324-330. (Pubitemid 41102427)
15. Sfikakis PP, Markomichelakis N, Alpsoy E et al (2007) Anti-TNF therapy in the management of Behcet's disease-review and basis for recommendations. Rheumatology (Oxford) 46:736-741. (Pubitemid 47061701)
16. Dé Tran QH, Guay E, Chartier S, Tousignant J (2001) Tacrolimus in dermatology. J Cutan Med Surg 5:329-335. (Pubitemid 32843790)
17. Bruynzeel I, Van Der Raaij LM, Willemze R, Stoof TJ (1997) Pentoxifylline inhibits human T-cell adhesion to dermal endothelial cells. Arch Dermatol Res 289:189-193. (Pubitemid 27170471)
18. Funk JO, Ernst M, Schonharting MM, Zabel P (1995) Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A. Int J Immunopharmacol 17:1007-1016. (Pubitemid 26097583)
19. Zouboulis CC, Orfanos CE (1998) Treatment of Adamantiades- Behçet disease with systemic interferon alfa. Arch Dermatol 134:1010-1016. (Pubitemid 28385325)
20. Nakamura T, Yagi H, Kurachi K, Konno H (2006) Intestinal Behcet's disease with pyoderma gangrenosum: a case report. World J Gastroenterol 12:979-981.
21. Fresko I, Yazici H (2008) Treatment strategies for Behçet's disease. Expert Opin Pharmacother 9:3211-3219.
22. Choi IJ, Kim JS, Cha SD et al (2000) Long-term clinical course and prognostic factors in intestinal Behçet's disease. Dis Colon Rectum 43:692-700. (Pubitemid 30324610)
23. Lee KS, Kim SJ, Lee BC et al (1997) Surgical treatment of intestinal Behçet's disease. Yonsei Med J 38:455-460. (Pubitemid 128516407)
24. Kurata M, Nozue M, Seino K et al (2006) Indications for surgery in intestinal Behçet's disease. Hepatogastroenterology 53:60-63. (Pubitemid 43287395)
25. Sapadin AN, Fleischmajer R (2006) Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54:258-265. (Pubitemid 43144395)
26. Deuter CM, Kotter I, Wallace GR et al (2008) Behçet's disease: ocular effects and treatment. Prog Retin Eye Res 27:111-136.
27. Kaçmaz RO, Kempen JH, Newcomb C et al (2008) Systemic immunosuppressive therapy for eye diseases cohort study group. Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 146:828-836.
28. Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of Infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine and corticosteroids in Behcet disease: an open-label trial. Arthritis Rheum 52:2478-2484. (Pubitemid 41117435)
29. Yazici H, Pazarli H, Barnes CG et al (1990) A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 322:281-285. (Pubitemid 20046329)
30. Akman-Demir G, Ayranci O, Kurtuncu M et al (2008) Cyclosporine for Behçet's uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 26(Suppl): S84-S90.
31. Krause L, Altenburg A, Pleyer U et al (2008) Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a. J Rheumatol 35:896-903. (Pubitemid 351747134)
32. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R et al (2006) Neovascularization of the optic disc in Behçet's disease. Jpn J Ophthalmol 50:256-265. (Pubitemid 43882002)
33. Sfikakis PP (2002) Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61(Suppl 2):ii51-ii53. (Pubitemid 35221714)
34. Elezoglou A, Kafasi N, Kaklamanis PH et al (2007) Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease. Clin Exp Rheumatol 25(Suppl):S65-S69.
35. Krause L, Altenburg A, Bechrakis NE et al (2007) Intraocular surgery under systemic interferon-alpha therapy in ocular Adamantiades-Behçet's disease. Graefes Arch Clin Exp Ophthalmol 245:1617-1621. (Pubitemid 47491549)
36. Elgin U, Berker N, Batman A, Soykan E (2007) Nd:YAG laser iridotomy in the management of secondary glaucoma associated with Behçet's disease. Eur J Ophthalmol 17:191-195. (Pubitemid 46918104)
37. Sullu Y, Alotaiby H, Beden U, Erkan D (2005) Pars plana vitrectomy for ocular complications of Behçet's disease. Ophthalmic Surg Lasers Imaging 36:292-297. (Pubitemid 41073105)
38. Soylu M, Demircan N, Pelit A (2001) Pars plana vitrectomy in ocular Behçet's disease. Int Ophthalmol 24:219-223. (Pubitemid 36372091)
39. Han JK, Kim HK, Kim YJ et al (2009) Behçet's disease as a frequently unrecognized cause of aortic regurgitation: suggestive and misleading echocardiography findings. J Am Soc Echocardiogr 22:1269-1274.
40. Marzban M, Mandegar MH, Karimi A et al (2008) Cardiac and great vessel involvement in "Behcet's disease". J Card Surg 23:765-768.
41. Imazio M, Brucato A, Trinchero R et al (2009) Colchicine for pericarditis: hype or hope? Eur Heart J 30:532-539.
42. Arishiro K, Nariyama J, Hoshiga M et al (2006) Vascular Behçet's disease with coronary artery aneurysm. Intern Med 45:903-907. (Pubitemid 44323007)
43. Ozen S, Bilginer Y, Besbas N et al (2010) Behçet disease: treatment of vascular involvement in children. Eur J Pediatr 169:427-430.
44. Oh SH, Lee JH, Shin JU, Bang D (2008) Dermatological features in Behçet disease-associated vena cava obstruction. Br J Dermatol 159:555-560.
45. Alpagut U, Ugurlucan M, Dayioglu E (2007) Major arterial involvement and review of Behçet's disease. Ann Vasc Surg 21:232-239. (Pubitemid 46367534)
46. Abdul-Hussien H, Hanemaaijer R, Verheijen JH et al (2009) Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content. J Vasc Surg 49:741-749.
47. Siva A, Saip S (2009) The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis. J Neurol 256:513-529.
48. Borhani Haghighi A (2009) Treatment of neuro-Behçet's disease: an update. Expert Rev Neurother 9:565-574.
49. Gono T, Murata M, Kawaguchi Y et al (2009) Successful treatment for sympathetic storms in a patient with neuro- Behçet's disease. Clin Rheumatol 28:357-359.